MaxCyte, Inc. Q4 2025 Earnings Call Summary

• Performance was pressured by a 15% decline in activity from the company’s largest customer due to manufacturing site reorganization and inventory management.

• The business model saw a net loss of six SPL clinical programs in 2025 as biotech partners rationalized portfolios and conserved capital.

• Management attributes the current revenue trajectory to short-term headwinds from discontinued programs rather than a fundamental shift in technology demand.

• The launch of ExPERT DTX represents a strategic pivot to capture customers at the earliest research stages, creating a ‘seamless path’ to clinical scale-up.

• Operational efficiency improved significantly following a restructuring that reduced annual cash burn by over $16 million compared to the prior model.

• The integration of SecurDx is positioning the company to address the evolving regulatory focus on off-target risk assessment in gene editing.

• 2026 guidance assumes a $4 million core revenue headwind from the annualized impact of 2025 program exits and inventory stabilization at the largest customer.

• Revenue is expected to be back-half weighted, with Q1 projected as the lightest quarter for core revenue as the new base stabilizes.

• The company anticipates five clinical programs entering pivotal studies over the next 18 months, which are expected to drive milestone and royalty growth through 2028.

• Guidance for SPL program-related revenue includes approximately $2 million in royalties from the commercial ramp of CASGEVY.

• Management expects to maintain a flat operating expense profile, leveraging the new cost structure to further reduce cash burn as revenue growth returns.

• A non-cash goodwill impairment of $3.6 million was recorded in Q4 2025, though management notes that these headwinds do not change the fundamentals of the business

• Twelve existing SPL agreements are now classified as inactive due to partners exiting the ex vivo space or ceasing operations.

• One SPL customer recently issued a termination notice for reasons unrelated to platform performance, which is factored into the 2026 guidance.

• The transition of the CFO role to Parmeet Ahuja, effective March 30, is intended to strengthen financial infrastructure for future scaling.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

• Management clarified that the projected decline is due to specific 2025 program losses and inventory drawdowns, not a lack of market demand.

• The 2026 guidance does not assume a macro recovery; any industry-wide demand improvement would represent upside to the current outlook.